The cancer immunotherapy programme at IGP comprises nine research groups that employ complementary approaches to study the role of the immune system in cancer. We also apply various methods to induce an immune attack on cancer cells. The research within the programme is both preclinical and clinical in nature, with preclinical developments being translated into early phase clinical trials.
New immunotherapy approaches
There is a strong focus on developing and verifying novel immunotherapy approaches as well as understanding mechanisms behind resistance to immunotherapy. Pathological examinations focus on understanding the immune landscape and the role of different immune cells in various forms of cancer. The clinical research includes both First-in-Human clinical trials with immunotherapies developed at IGP, and larger multi-center clinical trials.
The research groups within the programme work closely together and have at the same time a broad and international network of collaborators.
Rose-Marie Amini – Haematopathology
Gunilla Enblad – Tumour biology and clinical studies of lymphomas and prostate cancer
Magnus Essand – Gene, cell and immunotherapy of cancer
Mats Hellström – Translational research on immunotherapy for glioblastoma
Olle Korsgren – Diabetes research
Angelica Loskog – Immunotherapy for cancer and autoimmune diseases
Yumeng Mao – Dissecting the negative immune regulatory network to improve cancer immunotherapy
Patrick Micke – Integrative lung cancer pathology